companydata.dkEurofins BioPharma Product Testing Denmark Holding A/S: Financial statements 2023
CVR: 37064408
Eurofins BioPharma Product Testing Denmark Holding A/S (CVR 37064408) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -92,640 and a net result of DKK 3,606,153 compared with DKK 7,900,329 the year before. Equity amounted to DKK 20,107,893. The solvency ratio was 30.2%.
- Gross Profit
- -92,640 kr.
- Profit/Loss
- 3,606,153 kr.
- Equity
- 20,107,893 kr.
- Total Assets
- 66,546,856 kr.
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -93 t. | 3.6 mio. | 20.1 mio. | - |
| 2022 | - | -88 t. | 7.9 mio. | 18.8 mio. | - |
| 2021 | - | -82 t. | 4.3 mio. | 15.2 mio. | - |
| 2020 | - | -80 t. | 5.3 mio. | 15.9 mio. | - |
| 2019 | - | -81 t. | 3.3 mio. | 13.6 mio. | - |
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Eurofins BioPharma Product Testing Denmark Holding A/S has published its annual report for 2022. Gross profit came to DKK -87,649, and the net result was DKK 7,900,329.
About Eurofins BioPharma Product Testing Denmark Holding A/S
Eurofins BioPharma Product Testing Denmark Holding A/S is a Danish company of the type Aktieselskab based in Galten, founded in 2015. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Stefánia Pcolová. The company is owned by Eurofins Pharma Services LUX Holding SARL. In 2025, the company reported a gross profit of DKK -163,266 and a net result of DKK 8,356,614 compared with DKK -1,877,244 the year before. Equity amounted to DKK 24,787,263.